GO
Loading...

Think Pfizer will come back to AstraZenaca: Pro

Friday, 2 May 2014 | 2:16 PM ET

Astrazenaca has rejected Pfizer's $106 billion bid for the company. CNBC's Meg Tirrell, and Tim Chiang, CRT Capital senior analyst, discuss Pfizer's "opportunistic" strategy, and m&a in the pharma industry.